Акромегалія: настанови з клінічної практики ендокринологічного товариства (Частина 1)
DOI:
https://doi.org/10.1210/jc.2014-2700Анотація
Мета. Мета полягала в тому, щоб сформувати настанови з клінічної практики діагностики і лікування акромегалії.
Автори. До складу робочої групи ввійшли голова, обраний Підкомітетом з клінічних настанов (ПКН) Ендокринологічного товариства, п’ять експертів у галузі та методолог. Автори не отримували жодного корпоративного фінансування або винагороди. Розробка цих настанов частково фінансувалася Європейським товариством ендокринологів.
Доказові дані. Ці настанови, засновані на принципах доказової медицини, розроблено з використанням системи розробки, оцінки й експертизи рекомендацій (Grading of Recommendations, Assessment, Development and Evaluation) (GRADE), яка характеризує як ступінь переконливості рекомендацій, так і якість доказових даних. Робоча група проаналізувала основні доказові дані й ініціювала підготовку двох додаткових систематичних оглядів.
Процес досягнення консенсусу. Процес досягнення консенсусу включав одне засідання групи, кілька телеконференцій та листування електронною поштою. Проекти настанов переглянуто комітетами й членами Ендокринологічного товариства і Європейського товариства ендокринологів.
Висновки. Використовуючи підхід, заснований на принципах доказової медицини, ці настанови розглядають важливі клінічні питання, що стосуються обстеження та ведення пацієнтів з акромегалією, в тому числі належних біохімічних аналізів, розробки алгоритмів лікування (застосування медикаментозної монотерапії або комбінованої терапії) і ведення пацієнтів під час вагітності. (J Clin Endocrinol Metab 99: 3933-3951, 2014, DOI: http://dx.doi.org/10.1210/jc.2014-2700)
Посилання
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490–1494. https://doi.org/10.1136/bmj.328.7454.1490
Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666–673. https://doi.org/10.1210/jc.2007-1907
Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355:2558–2573. https://doi.org/10.1056/nejmx070007
Ribeiro-Oliveira A Jr, Barkan A. The changing face of acromegaly–advances in diagnosis and treatment. Nat Rev Endocrinol. 2012;8:605–611. https://doi.org/10.1038/nrendo.2012.101
Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189–3202. https://doi.org/10.1172/jci39375
Ben-Shlomo A, Pichurin O, Khalafi R, et al. Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis. Endocrinology. 2013;154:2399–2409. https://doi.org/10.1210/en.2013-1132
Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717–797. https://doi.org/10.1210/edrv.19.6.0353
Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters BK, Wierman ME. Clinical implications of growth hormone-secreting tumor subtypes. Endocrine. 2012;42:18–28. https://doi.org/10.1007/s12020-012-9660-9
Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K. Pathophysiology of acromegaly. Endocr Rev. 1983;4:271–290. https://doi.org/10.1210/edrv-4-3-271
Thorner MO, Martin WH, Rogol AD, et al. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab. 1980;51:438–445. https://doi.org/10.1210/jcem-51-3-438
Melmed S, Ezrin C, Kovacs K, Goodman RS, Frohman LA. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med. 1985;312:9–17. https://doi.org/10.1056/nejm198501033120103
Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257–266. https://doi.org/10.1038/nrendo.2011.40
Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228–1230. https://doi.org/10.1126/science.1126100
Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141–3148. https://doi.org/10.1210/jc.2009-2670
Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054–4058. https://doi.org/10.1210/jc.2002-011841
Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update: executive summary. Endocr Pract. 2011;17:636–646. https://doi.org/10.4158/ep.17.4.636
Faje AT, Barkan AL. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2010;95:2486–2491. https://doi.org/10.1210/jc.2009-2634
Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69–73. https://doi.org/10.1210/jcem-67-1-69
Lewitt MS, Saunders H, Cooney GJ, Baxter RC. Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. J Endocrinol. 1993;136:253–260. https://doi.org/10.1677/joe.0.1360253
Caregaro L, Favaro A, Santonastaso P, et al. Insulin-like growth factor 1 (IGF-1), a nutritional marker in patients with eating disorders. Clin Nutr. 2001;20:251–257. https://doi.org/10.1054/clnu.2001.0397
Clayton KL, Holly JM, Carlsson LM, et al. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf ). 1994;41:517–524. https://doi.org/10.1111/j.1365-2265.1994.tb02584.x
Weber MM, Auernhammer CJ, Lee PD, Engelhardt D, Zachoval R. Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopic liver transplantation. Horm Res. 2002;57:105–112. https://doi.org/10.1159/000057960
Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87:3537–3542. https://doi.org/10.1210/jcem.87.8.8658
Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14:284–294. https://doi.org/10.1007/s11102-011-0310-7
Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99:1712–1721. https://doi.org/10.1210/jc.2013-3059
Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays–a 2009 update. Growth Horm IGF Res. 2010;20:8–18. https://doi.org/10.1016/j.ghir.2009.09.004
Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf ). 2007;67:65–70. https://doi.org/10.1111/j.1365-2265.2007.02836.x
Barkan AL, Stred SE, Reno K, et al. Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab. 1989;69:1225–1233. https://doi.org/10.1210/jcem-69-6-1225
Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab. 2005;90:2117–2121. https://doi.org/10.1210/jc.2004-0875
Bangham DR, Gaines Das RE, Schulster D. The international standard for human growth hormone for bioassay: calibration and characterization by international collaborative study. Mol Cell Endocrinol. 1985;42:269–282. https://doi.org/10.1016/0303-7207(85)90058-9
Karavitaki N, Turner HE, Adams CB, et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf ). 2008;68:970–975. https://doi.org/10.1111/j.1365-2265.2007.03139.x
Arafat AM, Möhlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab.2008;93:1254–1262. https://doi.org/10.1210/jc.2007-2084
Markkanen H, Pekkarinen T, Välimäki MJ, et al. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clin Chem. 2006;52:468–473. https://doi.org/10.1373/clinchem.2005.060236
Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab. 2002;87:3142–3147. https://doi.org/10.1210/jcem.87.7.8631
Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16:294–302. https://doi.org/10.1007/s11102-012-0420-x
Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94:523–527. https://doi.org/10.1210/jc.2008-1371
Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. 2003;6:175–180. https://doi.org/10.1023/b:pitu.0000023424.72021.e2
Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301–342. https://doi.org/10.1210/er.2009-0033
Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555–559. https://doi.org/10.1373/clinchem.2010.150631
Karavitaki N, Fernandez A, Fazal-Sanderson V, Wass JA. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clin Endocrinol (Oxf ). 2009;71:840–845. https://doi.org/10.1111/j.1365-2265.2009.03578.x
Sherlock M, Aragon Alonso A, Reulen RC, et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf ). 2009;71:74–81. https://doi.org/10.1111/j.1365-2265.2008.03461.x
Jayasena CN, Wujanto C, Donaldson M, Todd JF, Meeran K. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients. Clin Endocrinol (Oxf ). 2008;68:36–41. https://doi.org/10.1111/j.1365-2265.2007.02996.x
Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011;96:1633–1641. https://doi.org/10.1210/jc.2011-0168
Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–446. https://doi.org/10.1530/eje.0.1510439
Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology. 2003;228:533–538. https://doi.org/10.1148/radiol.2282020695
Puig-Domingo M, Resmini E, Gomez-Anson B, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95:4973–4978. https://doi.org/10.1210/jc.2010-0573
Daud S, Hamrahian AH, Weil RJ, Hamaty M, Prayson RA, Olansky L. Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration? Pituitary. 2011;14:414–417. https://doi.org/10.1007/s11102-009-0205-z
Borson-Chazot F, Garby L, Raverot G, et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Ann Endocrinol (Paris). 2012;73:497–502. https://doi.org/10.1016/j.ando.2012.09.004
Kan E, Kan EK, Atmaca A, Atmaca H, Colak R. Visual field defects in 23 acromegalic patients. Int Ophthalmol. 2013;33:521–525. https://doi.org/10.1007/s10792-013-9733-7
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102–152. https://doi.org/10.1210/er.2002-0022
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89–95. https://doi.org/10.1530/eje-08-0267
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93:61–67. https://doi.org/10.1210/jc.2007-1191
Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary. 2011;14:276–383. https://doi.org/10.1007/s11102-011-0308-1
Mosca S, Paolillo S, Colao A, et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013;167:1712–1718. https://doi.org/10.1016/j.ijcard.2012.11.109
Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189–198. https://doi.org/10.1530/eje-12-0084
Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf ). 2010;72:203–208. https://doi.org/10.1111/j.1365-2265.2009.03626.x
Fieffe S, Morange I, Petrossians P, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011;164:877–884. https://doi.org/10.1530/eje-10-1050
Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf ). 2005;63:470–476. https://doi.org/10.1111/j.1365-2265.2005.02370.x
Tan KC, Shiu SW, Janus ED, Lam KS. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis. 1997;129:59–65. https://doi.org/10.1016/s0021-9150(96)06015-7
Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010;95:483–495. https://doi.org/10.1210/jc.2009-1912
Davi’ MV, Dalle Carbonare L, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159:533–540. https://doi.org/10.1530/eje-08-0442
Roemmler J, Gutt B, Fischer R, et al. Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep Breath. 2012;16:1247–1253. https://doi.org/10.1007/s11325-011-0641-7
Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008;22:639–657. https://doi.org/10.1016/j.beem.2008.08.011
Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008;9:41–58. https://doi.org/10.1007/s11154-007-9063-z
Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14:3484–3489. https://doi.org/10.3748/wjg.14.3484
Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab. 2005;90:84–90. https://doi.org/10.1210/jc.2004-0240
Dworakowska D, Gueorguiev M, Kelly P, et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol. 2010;163:21–28. https://doi.org/10.1530/eje-09-1080
Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T. Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine. 2014;45:114–121. https://doi.org/10.1007/s12020-013-9981-3
Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary. 2010;13:242–248. https://doi.org/10.1007/s11102-010-0224-9
Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730–2734. https://doi.org/10.1210/jcem.83.8.5007
Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73:233–240.
Jadresic A, Banks LM, Child DF, et al. The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med. 1982;51:189–204.
Lopes MB. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus. 2010;29:E2. https://doi.org/10.3171/2010.7.focus10169
Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly–meta-analysis and systematic review. PLoS One. 2014;9:88787. https://doi.org/10.1371/journal.pone.0088787
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90:2731–2739. https://doi.org/10.1210/jc.2004-2297
Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011;164:475–483. https://doi.org/10.1530/eje-10-1005
Bolanowski M, Daroszewski J, Medra M, Zadrozna-Sliwka B. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab. 2006;24:72–78. https://doi.org/10.1007/s00774-005-0649-9
Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf ). 1998;48:59–65. https://doi.org/10.1046/j.1365-2265.1998.00349.x
Tagliafico A, Resmini E, Nizzo R, et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. J Clin Endocrinol Metab. 2008;93:905–909. https://doi.org/10.1210/jc.2007-1719
Tagliafico A, Resmini E, Nizzo R, et al. The pathology of the ulnar nerve in acromegaly. Eur J Endocrinol. 2008;159:369–373. https://doi.org/10.1530/eje-08-0327
Fava GA, Sonino N, Morphy MA. Psychosomatic view of endocrine disorders. Psychother Psychosom. 1993;59:20–33. https://doi.org/10.1159/000288641
Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary. 2002;5:17–19. https://doi.org/10.1023/a:1022145116901
Kanis JA, Gillingham FJ, Harris P, et al. Clinical and laboratory study of acromegaly: assessment before and one year after treatment. Q J Med. 1974;43:409–431.
Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21:597–614.
Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 2006;111:1–7. https://doi.org/10.1007/s00401-005-1093-6
Grynberg M, Salenave S, Young J, Chanson P. Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab. 2010;95:4518–4525. https://doi.org/10.1210/jc.2009-2815
Abu Dabrh AM, Asi N, Farah W, et al. Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99:4003-4014. https://doi.org/10.1210/jc.2014-2900
Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 1979;301:1138–1142. https://doi.org/10.1056/nejm197911223012102
Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90:1972–1978. https://doi.org/10.1210/jc.2004-2009
Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89:2789–2796. https://doi.org/10.1210/jc.2003-032041
Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667–674. https://doi.org/10.1210/jc.2003-031199
Sherlock M, Reulen RC, Aragon-Alonso A, et al. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab. 2014;99:478–485. https://doi.org/10.1210/jc.2013-2450
Pokrajac A, Claridge AG, Shakoor SK, Trainer PJ. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol. 2006;154:267–274. https://doi.org/10.1530/eje.1.02073
Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96:2732–2740. https://doi.org/10.1210/jc.2011-0554
Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98:3190–3198. https://doi.org/10.1210/jc.2013-1036
McLaughlin N, Laws ER, Oyesiku NM, Katznelson L, Kelly DF. Pituitary centers of excellence. Neurosurgery. 2012;71:916–924; discussion 924–926. https://doi.org/10.1227/neu.0b013e31826d5d06
Wass JA, Turner HE, Adams CB. The importance of locating a good pituitary surgeon. Pituitary. 1999;2:51–54.
Nosé V, Ezzat S, Horvath E, et al. Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med. 2011;135:640–646.
Zada G, Cavallo LM, Esposito F, et al. Transsphenoidal surgery in patients with acromegaly: operative strategies for overcoming technically challenging anatomical variations. Neurosurg Focus. 2010;29:E8. https://doi.org/10.3171/2010.8.focus10156
Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011;17(suppl 4):1–44. https://doi.org/10.4158/ep.17.s4.1
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509–1517. https://doi.org/10.1210/jc.2008-2421
Cappabianca P, Cavallo LM, Colao A, de Divitiis E. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg. 2002;97:293–298. https://doi.org/10.3171/jns.2002.97.2.0293
Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure.’ Eur J Endocrinol. 2005;152:379–387. https://doi.org/10.1530/eje.1.01863
Nemergut EC, Dumont AS, Barry UT, Laws ER. Perioperative management of patients undergoing transsphenoidal pituitary surgery. Anesth Analg. 2005;101:1170–1181. https://doi.org/10.1213/01.ane.0000166976.61650.ae
Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002;96:195–208. https://doi.org/10.3171/jns.2002.96.2.0195
Rieger A, Rainov NG, Ebel H, et al. Factors predicting pituitary adenoma invasiveness in acromegalic patients. Neurosurg Rev. 1997;20:182–187. https://doi.org/10.1007/bf01105562
Wolfsberger S, Knosp E. Comments on the WHO 2004 classification of pituitary tumors. Acta Neuropathol. 2006;111:66–67. https://doi.org/10.1007/s00401-005-1097-2
Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86:4072–4077. https://doi.org/10.1210/jcem.86.9.7819
Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152:61–66. https://doi.org/10.1530/eje.1.01824
Wilson TJ, McKean EL, Barkan AL, Chandler WF, Sullivan SE. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary. 2013;16:459–464. https://doi.org/10.1007/s11102-012-0457-x
Yamada S, Fukuhara N, Oyama K, Takeshita A, Takeuchi Y. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly. Neurosurgery. 2010;67:949–956. https://doi.org/10.1227/neu.0b013e3181ec4379
Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93:2984–2990. https://doi.org/10.1210/jc.2008-0315
Mao ZG, Zhu YH, Tang HL, et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol. 2010;162:661–666. https://doi.org/10.1530/eje-09-0908
Shen M, Shou X, Wang Y, et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J. 2010;57:1035–1044. https://doi.org/10.1507/endocrj.k10e-203
Seidman PA, Kofke WA, Policare R, Young M. Anaesthetic complications of acromegaly. Br J Anaesth. 2000;84:179–182. https://doi.org/10.1093/oxfordjournals.bja.a013400
Khan ZH, Rasouli MR. Intubation in patients with acromegaly: experience in more than 800 patients. Eur J Anaesthesiol. 2009;26:354–355. https://doi.org/10.1097/eja.0b013e32831bc6fb
Friedel ME, Johnston DR, Singhal S, et al. Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors. Otolaryngol Head Neck Surg. 2013;149:840–844. https://doi.org/10.1177/0194599813507236
Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med. 2002;112:610–616. https://doi.org/10.1016/s0002-9343(02)01094-x
Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest. 2002;25:971–976. https://doi.org/10.1007/bf03344070
Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol. 1999;83:1506–1509, A8. https://doi.org/10.1016/s0002-9149(99)00135-6
Colao A, Attanasio R, Pivonello R, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91:85–92. https://doi.org/10.1210/jc.2005-1208
Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly: is there still a place for radiotherapy? Pituitary. 2007;10:53–59. https://doi.org/10.1007/s11102-007-0002-5
Krieger MD, Couldwell WT, Weiss MH. Assessment of long-term remission of acromegaly following surgery. J Neurosurg. 2003;98:719–724. https://doi.org/10.3171/jns.2003.98.4.0719
Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf ). 2009;71:166–170. https://doi.org/10.1111/j.1365-2265.2009.03556.x
Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of «abnormal» nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89:495–500. https://doi.org/10.1210/jc.2003-031316
Kim EH, Oh MC, Lee EJ, Kim SH. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery. 2012;70:1106–1113; discussion 1113. https://doi.org/10.1227/neu.0b013e31823f5c16
Dina TS, Feaster SH, Laws ER Jr, Davis DO. MR of the pituitary gland postsurgery: serial MR studies following transsphenoidal resection. Am J Neuroradiol. 1993;14:763–769.
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465–4473. https://doi.org/10.1210/jc.2005-0260
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2016 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
